As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
Allergic rhinitis in children is common. According to the international study of asthma and
allergies in childhood (ISAAC) phase III, the global prevalence of allergic rhinitis among
children is increasing to 40.1% and the prevalence of allergic rhinitis in Bangkok area in
2018, among children aged 6-7 and 13-14 years was 16.32%. This disease is a global health
problem affecting quality of life of patients in daily life, work, study and sleep.
Intranasal corticosteroid is the most effective treatment for allergic rhinitis. From real
world evidence; most of allergic rhinitis patient use the drug when symptoms worsen. In
children, the use of intranasal corticosteroid may cause minor local side effects such as
dryness, burning sensation or epistaxis. In some intranasal corticosteroid, long-term use may
result in decreased growth compared to placebo which make parents concern.
The investigators interested in studying the efficacy of intranasal corticosteroid comparing
between daily use and as needed use in children with allergic rhinitis. To study the
appropriate form of treatment to increase cooperation. Patient will have a better quality of
life and reduce the risk of side effects from prolonged use of intranasal corticosteroid.
From the literature review, it was found that most studies were conducted among adult
patients with seasonal allergic rhinitis In Thailand in 2020, Thongngam et al. studied the
efficacy of intranasal corticosteroid was compared between daily use and as needed use in
adult patients with perennial allergic rhinitis. The results of the study concluded that the
daily use group can reduced more TNSS (total nasal symptoms score) but was not statistically
significant and had a greater increase in peak nasal inspiratory flow (PNIF) compared to as
needed group. Interestingly, the quality of life assessment (RCQ-36 score) in both2 groups
improved equally, In as needed group, the cumulative dose was 51% lower than the daily dose
group.
The investigators want to compare the efficacy of intranasal corticosteroid between daily
versus as needed use in children with perennial allergic rhinitis which had not been studied
before.